SAN DIEGO, May 12, 2011 /PRNewswire/ -- Naviscan, Inc., the leader in 3D Molecular Breast Imaging (MBI), has entered into a distribution agreement with Chindex Medical Limited to market and service Naviscan's high-resolution organ-specific PET scanner in the People's Republic of China, including Hong Kong and Macau. The agreement represents the introduction of PEM (Positron Emission Mammography), the scanner's breast application, as a new tool available to Chinese women in their fight against breast cancer.
Naviscan manufactures the only commercially-available PEM scanner and PEM-guided biopsy system. The scanner uses PET technology to produce tomographic images that allow physicians to visualize and biopsy breast tumors as small as 1.3 mm, the width of a grain of rice. In recently published data, PEM has been found to be significantly more precise at identifying benign and cancerous lesions, in what scientists call "specificity", therefore reducing the number of unnecessary biopsies. This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma and cost associated with unnecessary procedures.
Chindex Medical Limited is a specialized full-service distributor of high tech medical equipment in Greater China, including a strong presence in the minimally-invasive surgical and imaging sectors as the exclusive distributor for the Intuitive Surgical daVinci® Surgical Systems, and Siemens high-end ultrasound and Hologic mammography products. The Naviscan PET scanner is an ideal complement to Chindex Medical Limited's breast and surgery expertise and an ideal partner to continue its expansion in Asia.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com
About Chindex Medical Limited
Chindex Medical Limited is a joint venture between Fosun Pharma and Chindex International, Inc. with manufacturing and distribution businesses serving both domestic China and export markets. Combining Chindex's more than thirty years of experience as a leading provider of capital equipment in China with FosunPharma's development over the past fifteen years as the largest private medical and pharmaceutical enterprise in China, the Company's vision is to become a global leader in the healthcare market. Additional information can be found at http://www.chindex.com/cml/index.html
|SOURCE Naviscan, Inc.|
Copyright©2010 PR Newswire.
All rights reserved